GSK PLC 2002 SR
The report highlights GlaxoSmithKline's corporate and social responsibility activities for 2002, focusing on its mission to improve global health. The company invested £239 million in community activities and donated 66 million albendazole tablets to combat lymphatic filariasis. Significant progress was made in providing preferentially-priced HIV/AIDS and malaria treatments to developing nations. GSK also emphasized its commitment to ethical R&D, diversity, and environmental sustainability, including a plan to eliminate CFCs from inhalers. A new risk management and compliance framework was implemented to ensure high standards of business ethics across its global operations.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2002
Type: SR
Pages: 36
Back to company
GSK PLC
Corporate And Social Responsibility Report
The report highlights GlaxoSmithKline's corporate and social responsibility activities for 2002, focusing on its mission to improve global health. The company invested £239 million in community activities and donated 66 million albendazole tablets to combat lymphatic filariasis. Significant progress was made in providing preferentially-priced HIV/AIDS and malaria treatments to developing nations. GSK also emphasized its commitment to ethical R&D, diversity, and environmental sustainability, including a plan to eliminate CFCs from inhalers. A new risk management and compliance framework was implemented to ensure high standards of business ethics across its global operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2002
Reporting Period
Jan 1, 2002 - Dec 31, 2002
Fiscal Year
2002
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees